Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfa-2a (Roche)
- Development stage
- Discontinued
- Lead developer
- Roche
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
**Interferon alfa-2a** is a recombinant, non-glycosylated human type I interferon cytokine produced in *Escherichia coli*. It binds the interferon-alpha/beta receptor subunits IFNAR1 and IFNAR2, activating JAK-STAT-mediated transcriptional programs with antiviral, antiproliferative, immunomodulatory, and antitumor effects. In Eastern Cooperative Oncology Group study E6296, it was administered subcutaneously at 9 million units three times weekly as one component of the FHIG co-administration regimen with fluorouracil, hydroxyurea, and filgrastim for advanced gastric cancer. The phase II regimen had limited activity and was not advanced as a development platform for gastric cancer. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00003172))
- Brand names
- CanferonLaroferonRoferon-A
- Other names
- HuIFN-alphaAIFN-alpha-2aIFN-alpha2aIFN-alpha 2ainterferon alfa-2a, recombinantrecombinant human interferon alfa-2arecombinant leukocyte A interferonrIFN-alphaA
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on interferon alfa-2a (Roche).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfa-2a (Roche).